BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
We hosted the Zota Healthcare Ltd.’s management to discuss about the company’s business and expert view on generic penetration in India. Zota is exploring emerging opportunities in the generic pharmaceutical landscape.
Zota’s generic pharmacy chain Davaindia is India’s largest private sector retail generic pharmacy chain, whose core value proposition is providing quality generic medicines at substantial discounts of up to 90% compared to their branded equivalents.
Davaindia focuses exclusively on private label products in the medicinal, over-the-counter and ayurvedic categories, with a significant emphasis on chronic therapies and ailments. This one-of-its-kind concept that the company started with three stores in 2017 has scaled up to become the largest private sector generic pharmacy chain, with 550 plus active stores.
The company is making meaningful inroads into the generic retail pharmacy business. Including pharmacy chain, Zota’s business model comprises three verticals, namely domestic generics, export generics and retail pharmacy chain (Davaindia).
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.